Follicular dendritic cell tumors are rare spindle cell neoplasms that usually are identified as lymph node-based neoplasms, but can obscure the underlying lymph node or occur extranodally. [1] [2] [3] As the histologic differential diagnosis includes other dendritic cell tumors as well as other sarcomas and spindle cell neoplasms, the diagnosis has required immunohistochemical positivity for CD21, CD23, and/or CD35. Our previous publication documented that addition of a clusterin stain to this immunohistochemical panel enhances its diagnostic sensitivity for follicular dendritic cell tumor. 4 Fascin expression has also been proposed as a potential marker of dendritic cell neoplasms. [5] [6] [7] The specificity of these markers among a variety of sarcomas and other spindle cell neoplasms has not been established.
Interest in clusterin as a diagnostic marker began when gene array analysis identified its expression in anaplastic large cell lymphoma. 8 Since this report, it has been shown that 80-100% of systemic anaplastic large cell lymphomas and 40-60% of primary cutaneous anaplastic large cell lymphomas are immunohistochemically positive for clusterin. 9, 10 Additional immunohistochemical surveys among hematopoietic neoplasms have reported clusterin expression in a small subset (12%) of diffuse large B-cell lymphomas and rarely in cases of peripheral T-cell lymphoma and nodular sclerosis Hodgkin's lymphoma. 10, 11 Among nonhematopoietic neoplasms, overexpression of clusterin has been documented in carcinomas of the breast, colon, pancreas and prostate. [11] [12] [13] [14] The initial immunohistochemical studies using antibodies to fascin documented its expression in Reed-Sternberg cells of classical Hodgkin's lymphoma, and suggested that this might be evidence of the dendritic lineage of these cells. 6 While subsequent studies have shown that the neoplastic cells in Hodgkin's lymphoma are actually of B-cell lineage, the emphasis on fascin as a dendritic cell marker has remained. Indeed, it is expressed in the majority of follicular dendritic cell tumors, interdigitating dendritic cell tumors, and Langerhans cell histiocytoses. 2, 5, 15 The expression of fascin in other spindle cell tumors, however, has not been formally evaluated.
We collected 202 cases of a wide variety of sarcomas and spindle cell tumors from our files, with an emphasis on lesions that might enter the differential diagnosis of dendritic cell tumors. Immunohistochemical analysis of these cases was performed to determine the specificity of fascin and clusterin for dendritic cell neoplams.
Materials and methods
After Mayo Foundation Institutional Review Board approval had been obtained, formalin-fixed, paraffin-embedded blocks from a total of 202 previously diagnosed cases were retrieved from the Mayo Clinic archives. Data on 12 follicular dendritic cell tumors and six interdigitating dendritic cell tumors, including the histologic features of these cases, have been described in detail elsewhere. 4 Two additional cases of follicular dendritic cell tumor (a CD35-positive retroperitoneal mass and a CD21, CD23, CD35-positive peripancreatic mass) and one additional case of interdigitating dendritic cell tumor (an S100 positive lesion in a cervical lymph node) were included for a total of 14 and 7, respectively. The other cases included leiomyosarcoma (n ¼ 17), inflammatory myofibroblastic tumor (n ¼ 13), inflammatory pseudotumor (n ¼ 2), spindle cell thymoma (n ¼ 17), synovial sarcoma (n ¼ 11), fibrosarcoma (n ¼ 14), liposarcoma (n ¼ 27), gastrointestinal stromal tumor (n ¼ 13), malignant fibrous histiocytoma (n ¼ 18), angiomatoid fibrous histiocytoma (n ¼ 4), angiosarcoma (n ¼ 10), malignant peripheral nerve sheath tumor (n ¼ 8), desmoplastic (n ¼ 10) or spindle cell (n ¼ 6) malignant melanoma, and spindle cell carcinoma (n ¼ 11). The diagnosis was verified in each case by histomorphologic review and confirmatory immunostains when necessary.
Cases of inflammatory myofibroblastic tumor included a histologic spectrum of lesions with variable degrees of fibrosis, mixed inflammatory cell infiltrate and spindle cell proliferation, and all were negative for the follicular dendritic cell markers CD21, CD23 and CD35. The inflammatory myofibroblastic tumors were from various locations including liver (n ¼ 3), spleen (n ¼ 1, previously reported 16 ), lung (n ¼ 2), small bowel mesentery (n ¼ 3), pelvis (n ¼ 2), kidney (n ¼ 1), and spermatic cord (n ¼ 1). Two cases considered as reactive/ reparative inflammatory pseudotumors were from the orbit (n ¼ 1) and bladder (n ¼ 1). Liposarcoma cases included well-differentiated sclerosing (n ¼ 15), dedifferentiated (n ¼ 5), myxoid/round cell (n ¼ 3), and pleomorphic (n ¼ 4) types. Spindle cell carcinoma cases were from the lung (n ¼ 4),
Each case was subjected to immunohistochemical staining with antibodies directed against fascin and clusterin ( Table 1) . Positivity for each antigen was scored both quantitatively (negative, o50% or 450% of cells staining) and qualitatively (weak, moderate, or strong staining).
Results
The immunohistochemical results are summarized in Table 2 . The cases showing positive staining were divided into two categories. The category of focal and/or weak/moderate included cases with weak staining in 1-100% of the cells as well as those with moderate staining in o50% of the cells. The category of diffuse, moderate/strong included cases with moderate or strong staining in 450% of the cells.
Diffuse moderate or strong clusterin staining was 100% sensitive for follicular dendritic cell tumor ( Figure 1 ), and 93% specific for follicular dendritic cell tumor among the sarcomas and spindle cell neoplasms studied. Although a minor subset of many sarcomas showed weak or focal moderate clusterin staining (Figure 2a) , only rare cases of leiomyosarcoma (n ¼ 1), angiosarcoma (n ¼ 1) and fibrosarcoma (n ¼ 2) showed strong diffuse staining (Table 2 ). These four cases were confirmed to be immunohistochemically negative for CD21, CD23 and CD35. It was noted that areas of apoptotic/necrotic cells stained very strongly for clusterin even in tumors that did not express the protein in viable cells (Figure 2b ). These areas were therefore not used to judge clusterin positivity. Care was also taken not to overinterpret background staining due to clusterin positivity in secretions or serum. Clusterin staining as a single tool was least reliable in distinguishing follicular dendritic cell tumors from spindle cell thymomas or malignant fibrous histiocytoma ( Figure 3) .
In contrast, fascin staining was quite nonspecific among sarcomas and spindle cell neoplasms ( Figure  4 ). Diffuse, moderate or strong fascin staining was seen in the large majority of follicular dendritic cell tumors, interdigitating dendritic cell tumors, liposarcomas, synovial sarcomas, angiosarcomas, malignant melanomas, and spindle cell carcinomas, as well as in a significant subset of leiomyosarcomas, spindle cell thymomas, malignant fibrous histiocytomas and inflammatory myofibroblastic tumors.
Discussion
Our previous study indicated that strong clusterin staining is highly sensitive for follicular dendritic cell tumors, and that it also distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms including interdigitating dendritic cell tumors and Langerhans cell histiocytoses. 4 In this expanded immunohistochemical survey, we demonstrate that strong clusterin staining is 93% specific for follicular dendritic cell tumor among a variety of sarcomas and spindle cell neoplasms. In contrast, fascin staining is nonspecific among sarcomas and thus does not imply a dendritic cell lineage.
The reported findings indicate that a clusterin stain is a useful addition to an immunohistochemical panel in the evaluation of low-grade spindle cell neoplasms with features of follicular dendritic cell tumor, such as a whorling growth pattern and intimately admixed lymphocytes. Our previous study as well as others have documented that the traditional follicular dendritic cell markers CD21, CD23 and CD35 are sometimes limited by focality and variability in intensity of staining. 4, 17, 18 In addition, clusterin appears to have greater sensitivity for follicular dendritic cell tumor compared to CD21, CD23 and CD35. In our practice, we have found that strong clusterin staining in 450% of the cells is diagnostically useful in situations of morphologically unusual cases of FDCT that show positivity for CD21 or CD35, as well as in morphologically typical cases that lack expression of these antigens.
The clusterin glycoprotein is expressed in a variety of cell types, including the epithelial cells at most fluid-tissue boundaries, and appears to have diverse functions in the transport of lipoproteins, (14) 0 (0) 2 (14) 1 (7) 2 (14) Inflammatory myofibroblastic tumor (13) 2 (15) 4 (31) 1 (8) 0 (0) Inflammatory pseudotumor (2) 0 (0) 1 (50) 0 (0) 0 (0) Spindle cell thymoma (17) 6 (35) 7 (41) 5 (29) 5 (29) Malignant fibrous histiocytoma (18) 3 (17) 11 (61) 4 (22) 5 (28) Angiomatoid fibrous histiocytoma (4) 2 (50) 0 (0) 0 (0) 0 (0) Angiosarcoma (10) 0 (0) 10 (100) 3 (30) 1 (10) Melanoma, spindle cell (6) 0 (0) 5 (83) 2 (33) 0 (0) Melanoma, desmoplastic (10) 2 (20) 8 (80) 0 (0) 0 (0) Spindle cell carcinoma (11) 0 (0) 10 (91) 2 (18) 0 (0) w/m, weak to moderate staining; m/s, moderate or strong staining. inhibition of complement-mediated cell lysis, and as a stress-induced secreted chaperone protein, which protects other secreted proteins from degradation. 19 Initially, it was also implicated in the process of apoptotic cell death, but more recent studies have demonstrated that its enhanced expression in many apoptotic tissues is restricted to the vital neighboring cells, suggesting a cytoprotective role. 19, 20 Our observation that cells in areas of apoptosis or tumor necrosis showed strong clusterin staining by immunohistochemistry would be expected based on the apparent role of the protein in this process. It should be emphasized that enhanced clusterin expression was seen surrounding areas of necrosis even when the background tumor cells were negative, and these areas should be disregarded in terms of supportive evidence of follicular dendritic cell tumor. An additional potential pitfall in clusterin stain interpretation relates to its ubiquitous presence in serum and secretions. This occasionally resulted in increased background staining that should not be falsely interpreted as positivity within the neoplastic cells. Given the expression of clusterin in a wide variety of benign epithelial cells as well as in carcinomas of the breast, colon, pancreas, ovary, bladder and prostate, [11] [12] [13] [14] it is somewhat surprising that we did not observe strong clusterin staining in any of 11 spindle cell carcinomas. Our case selection was somewhat limited in its scope with the majority representing spindle cell squamous carcinomas from various locations. We can therefore not exclude the possibility that a subset of spindle cell carcinomas could show strong clusterin expression.
Clusterin staining was least reliable in distinguishing follicular dendritic cell tumors from malignant fibrous histiocytoma and spindle cell thymoma. Generally, this is a differential diagnosis that can be resolved with correlation of all clinicopathologic features. Follicular dendritic cell tumors can show pleomorphic cytology similar to malignant fibrous histiocytoma, as was observed in two of the 14 follicular dendritic cell tumors in this series (described in detail in the previous publication 4 ). In these cases, a search for areas more typical of follicular dendritic cell tumors and stains for CD21, CD23 and CD35 can help separate these entities since a clusterin stain alone is not a reliable discriminant.
Spindle cell (medullary) thymoma can be distinguished from follicular dendritic cell tumor by cytokeratin positivity and an anterior mediastinal location. In situ hybridization studies have localized expression of clusterin mRNA to thymic medullary epithelial cells, 21 and our immunohistochemical studies confirm this in neoplastic thymic epithelium. Spindle cell thymomas share many histologic features with follicular dendritic cell tumors, including nodules or whorls of spindled cells with vesicular nuclei, perivascular spaces, and intermixed lymphocytes. The strong expression of clusterin may suggest that medullary cells of the thymus also have physiologic similarities to follicular dendritic cells. The interaction of follicular dendritic cells with activated, antigen-specific B cells serves to rescue them from apoptosis and promote the development of memory B cells. 22 Given its purported cytoprotective role, the secreted clusterin protein may be involved in this process. It is plausible that clusterin may serve a similar role in the interaction between thymic medullary epithelial cells and immature T cells.
In contrast to the specificity of strong clusterin staining, fascin staining was found in the majority of spindle cell tumors included in the study. Therefore, it does not provide evidence of dendritic cell lineage, as has been suggested.
In conclusion, we have demonstrated that clusterin immunostaining is of significant utility in the diagnostic evaluation of sarcomas and spindle cell neoplasms. Diffuse, strong clusterin staining showed 100% sensitivity and 93% specificity for follicular dendritic cell tumor, and therefore is a useful supplemental marker to identify this neoplasm. Fascin staining does not appear to have a role in the diagnosis of spindle cell neoplasms.
